- Home
- CRIS vs ELEV Comparison
CRIS vs ELEV Comparison
Compare CRIS & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- ELEV
- Stock Information
- Founded
- CRIS 2000
- ELEV 2019
- Country
- CRIS United States
- ELEV United States
- Employees
- CRIS N/A
- ELEV N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- CRIS Health Care
- ELEV Health Care
- Exchange
- CRIS Nasdaq
- ELEV Nasdaq
- Market Cap
- CRIS 32.8M
- ELEV 37.6M
- IPO Year
- CRIS 2000
- ELEV 2021
- Fundamental
- Price
- CRIS $3.29
- ELEV $0.71
- Analyst Decision
- CRIS Strong Buy
- ELEV Buy
- Analyst Count
- CRIS 3
- ELEV 6
- Target Price
- CRIS $23.00
- ELEV $7.20
- AVG Volume (30 Days)
- CRIS 243.3K
- ELEV 4.2M
- Earning Date
- CRIS 02-06-2025
- ELEV 03-05-2025
- Dividend Yield
- CRIS N/A
- ELEV N/A
- EPS Growth
- CRIS N/A
- ELEV N/A
- EPS
- CRIS N/A
- ELEV N/A
- Revenue
- CRIS $10,259,000.00
- ELEV N/A
- Revenue This Year
- CRIS N/A
- ELEV N/A
- Revenue Next Year
- CRIS N/A
- ELEV N/A
- P/E Ratio
- CRIS N/A
- ELEV N/A
- Revenue Growth
- CRIS 0.44
- ELEV N/A
- 52 Week Low
- CRIS $2.86
- ELEV $0.50
- 52 Week High
- CRIS $17.49
- ELEV $5.83
- Technical
- Relative Strength Index (RSI)
- CRIS 44.97
- ELEV 53.28
- Support Level
- CRIS $3.10
- ELEV $0.65
- Resistance Level
- CRIS $3.60
- ELEV $0.98
- Average True Range (ATR)
- CRIS 0.37
- ELEV 0.11
- MACD
- CRIS 0.00
- ELEV 0.00
- Stochastic Oscillator
- CRIS 26.22
- ELEV 36.63
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.